Literature DB >> 12562926

Amyloid beta(1-42) peptide alters the gating of human and mouse alpha-bungarotoxin-sensitive nicotinic receptors.

Francesca Grassi1, Eleonora Palma, Raffaella Tonini, Mascia Amici, Marc Ballivet, Fabrizio Eusebi.   

Abstract

The beta-amyloid(1-42) peptide (Abeta(1-42)), a major constituent of the Alzheimer's disease amyloid plaque, specifically binds to the neuronal alpha-bungarotoxin (alpha-BuTx)-sensitive alpha7 nicotinic acetylcholine receptor (alpha7 nAChR). Accordingly, Abeta1-42 interferes with the function of alpha7 nAChRs in chick and rodent neurons. To gain insights into the human disease, we studied the action of Abeta(1-42) on human alpha7 nAChRs expressed in Xenopus oocytes. In voltage-clamped oocytes expressing the wild-type receptor, Abeta(1-42) blocked ACh-evoked currents. The block was non-competitive, required over 100 s to develop and was partially reversible. In oocytes expressing the mutant L248T receptor, Abeta(1-42) activated methyllycaconitine-sensitive currents in a dose-dependent manner. Peptide-evoked unitary events, recorded in outside-out patches, showed single-channel conductances and open duration comparable to ACh-evoked events. Abeta(1-42) had no effect on the currents evoked by glutamate, GABA or glycine in oocytes expressing human or mouse receptors for these transmitters. Muscle nAChRs are also alpha-BuTx-sensitive and we therefore investigated whether they respond to Abeta(1-42). In human kidney BOSC 23 cells expressing the fetal or adult mouse muscle nAChRs, Abeta(1-42) blocked ACh-evoked whole-cell currents, accelerating their decay. Outside-out single-channel recordings showed that the block was due to a reduced channel open probability and enhanced block upon ACh application. We also report that the inverse peptide Abeta(42-1), but not Abeta(40-1), partially mimicked the effects of the physiological Abeta(1-42) peptide. Possible implications for degenerative neuronal and muscular diseases are discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12562926      PMCID: PMC2342606          DOI: 10.1113/jphysiol.2002.035436

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  39 in total

1.  Neuronal nicotinic threonine-for-leucine 247 alpha7 mutant receptors show different gating kinetics when activated by acetylcholine or by the noncompetitive agonist 5-hydroxytryptamine.

Authors:  E Palma; L Maggi; F Eusebi; R Miledi
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

2.  Patch clamp measurements on Xenopus laevis oocytes: currents through endogenous channels and implanted acetylcholine receptor and sodium channels.

Authors:  C Methfessel; V Witzemann; T Takahashi; M Mishina; S Numa; B Sakmann
Journal:  Pflugers Arch       Date:  1986-12       Impact factor: 3.657

3.  Identification of a determinant of acetylcholine receptor gating kinetics in the extracellular portion of the gamma subunit.

Authors:  S Fucile; A M Mileo; F Grassi; A M Salvatore; S Alemà; F Eusebi
Journal:  Eur J Neurosci       Date:  1996-12       Impact factor: 3.386

Review 4.  Alzheimer's disease: a re-examination of the amyloid hypothesis.

Authors:  R L Neve; N K Robakis
Journal:  Trends Neurosci       Date:  1998-01       Impact factor: 13.837

Review 5.  Normal and abnormal biology of the beta-amyloid precursor protein.

Authors:  D J Selkoe
Journal:  Annu Rev Neurosci       Date:  1994       Impact factor: 12.449

6.  Mutations in the channel domain alter desensitization of a neuronal nicotinic receptor.

Authors:  F Revah; D Bertrand; J L Galzi; A Devillers-Thiéry; C Mulle; N Hussy; S Bertrand; M Ballivet; J P Changeux
Journal:  Nature       Date:  1991-10-31       Impact factor: 49.962

7.  Expression of functional neurotransmitter receptors in Xenopus oocytes after injection of human brain membranes.

Authors:  Ricardo Miledi; Fabrizio Eusebi; Ataúlfo Martínez-Torres; Eleonora Palma; Flavia Trettel
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-17       Impact factor: 11.205

8.  Threonine-for-leucine mutation within domain M2 of the neuronal alpha(7) nicotinic receptor converts 5-hydroxytryptamine from antagonist to agonist.

Authors:  E Palma; A M Mileo; F Eusebi; R Miledi
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

9.  Similarities between beta amyloid peptides 1-40 and 40-1: effects on aggregation, toxicity in vitro, and injection in young and aged rats.

Authors:  T Giordano; J B Pan; L M Monteggia; T F Holzman; S W Snyder; G Krafft; H Ghanbari; N W Kowall
Journal:  Exp Neurol       Date:  1994-02       Impact factor: 5.330

10.  Secondary structure of amyloid beta peptide correlates with neurotoxic activity in vitro.

Authors:  L K Simmons; P C May; K J Tomaselli; R E Rydel; K S Fuson; E F Brigham; S Wright; I Lieberburg; G W Becker; D N Brems
Journal:  Mol Pharmacol       Date:  1994-03       Impact factor: 4.436

View more
  30 in total

Review 1.  Amyloid-β peptide: Dr. Jekyll or Mr. Hyde?

Authors:  Daniela Puzzo; Ottavio Arancio
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

2.  Virtual screening against acetylcholine binding protein.

Authors:  Maleeruk Utsintong; Piyanuch Rojsanga; Kwok-Yiu Ho; Todd T Talley; Arthur J Olson; Kinzo Matsumoto; Opa Vajragupta
Journal:  J Biomol Screen       Date:  2011-09-28

3.  Glutamatergic synapse formation is promoted by α7-containing nicotinic acetylcholine receptors.

Authors:  Adrian F Lozada; Xulong Wang; Natalia V Gounko; Kerri A Massey; Jingjing Duan; Zhaoping Liu; Darwin K Berg
Journal:  J Neurosci       Date:  2012-05-30       Impact factor: 6.167

Review 4.  The keystone of Alzheimer pathogenesis might be sought in Aβ physiology.

Authors:  D Puzzo; W Gulisano; O Arancio; A Palmeri
Journal:  Neuroscience       Date:  2015-08-24       Impact factor: 3.590

5.  Subtype-specific actions of beta-amyloid peptides on recombinant human neuronal nicotinic acetylcholine receptors (alpha7, alpha4beta2, alpha3beta4) expressed in Xenopus laevis oocytes.

Authors:  Luanda Pym; Mark Kemp; Valérie Raymond-Delpech; Steven Buckingham; C A R Boyd; David Sattelle
Journal:  Br J Pharmacol       Date:  2005-12       Impact factor: 8.739

Review 6.  Alzheimer's disease amyloid beta-protein and synaptic function.

Authors:  Tomas Ondrejcak; Igor Klyubin; Neng-Wei Hu; Andrew E Barry; William K Cullen; Michael J Rowan
Journal:  Neuromolecular Med       Date:  2009-09-16       Impact factor: 3.843

7.  The protein oxidation repair enzyme methionine sulfoxide reductase a modulates Aβ aggregation and toxicity in vivo.

Authors:  Alicia N Minniti; Macarena S Arrazola; Marcela Bravo-Zehnder; Francisca Ramos; Nibaldo C Inestrosa; Rebeca Aldunate
Journal:  Antioxid Redox Signal       Date:  2015-01-01       Impact factor: 8.401

8.  A novel nicotinic acetylcholine receptor subtype in basal forebrain cholinergic neurons with high sensitivity to amyloid peptides.

Authors:  Qiang Liu; Yao Huang; Fenqin Xue; Alain Simard; Jamie DeChon; Guohui Li; Jianliang Zhang; Linda Lucero; Min Wang; Michael Sierks; Gang Hu; Yongchang Chang; Ronald J Lukas; Jie Wu
Journal:  J Neurosci       Date:  2009-01-28       Impact factor: 6.167

9.  Inhibition of native and recombinant nicotinic acetylcholine receptors by the myristoylated alanine-rich C kinase substrate peptide.

Authors:  Elaine A Gay; Rebecca C Klein; Mark A Melton; Perry J Blackshear; Jerrel L Yakel
Journal:  J Pharmacol Exp Ther       Date:  2008-09-23       Impact factor: 4.030

10.  Modeling binding modes of alpha7 nicotinic acetylcholine receptor with ligands: the roles of Gln117 and other residues of the receptor in agonist binding.

Authors:  Xiaoqin Huang; Fang Zheng; Clare Stokes; Roger L Papke; Chang-Guo Zhan
Journal:  J Med Chem       Date:  2008-10-01       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.